Substance Use and Human Health: Alcohol, Tobacco, and Other Drugs

Substance use — encompassing alcohol consumption, tobacco and nicotine product use, and the misuse of illicit and prescription drugs — remains a primary driver of preventable death and disability across the United States. The federal landscape for addressing substance use disorders involves regulatory agencies, licensing bodies, classification systems, and treatment structures that span public health, behavioral health, and criminal justice sectors. This page provides a reference-level treatment of how substance use intersects with human health, including its definitions, causal pathways, classification frameworks, and the professional and institutional infrastructure that governs the sector.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix
• References

Definition and scope

Substance use, in the context of population and individual health, refers to the ingestion, inhalation, injection, or other self-administration of psychoactive compounds that alter cognition, mood, perception, or behavior. The Substance Abuse and Mental Health Services Administration (SAMHSA) distinguishes between substance use (any consumption), substance misuse (use that causes health or social problems, or use of a prescription medication outside its prescribed parameters), and substance use disorder (SUD), a clinical diagnosis codified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) published by the American Psychiatric Association.

Alcohol, tobacco, and other drugs collectively accounted for approximately 292,000 deaths per year in the United States as of the most recent CDC mortality analyses — a figure encompassing alcohol-related liver disease, lung cancer from smoking, and drug overdose fatalities. Drug overdose deaths alone reached 107,941 in 2022 (CDC WONDER Provisional Drug Overdose Death Counts). Tobacco use remains the single leading cause of preventable death, responsible for more than 480,000 deaths annually in the U.S. (CDC Tobacco-Related Mortality Fact Sheet).

The federal regulatory scope encompasses the Drug Enforcement Administration (DEA) for scheduling controlled substances, the Food and Drug Administration (FDA) for regulating tobacco products and medication-assisted treatments, SAMHSA for treatment system oversight and block grant funding, and the National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) for research. State-level licensing boards regulate treatment providers, counselors, and facilities. For additional context on how substance use fits within the broader taxonomy of health domains, the overview of how health systems operate at a conceptual level provides structural grounding.

Core mechanics or structure

Psychoactive substances exert their primary effects through interaction with neurotransmitter systems in the central nervous system. The specific mechanism varies by substance class:

• Alcohol (ethanol): Functions as a central nervous system depressant. Ethanol enhances gamma-aminobutyric acid (GABA) receptor activity, producing sedation and anxiolysis, while simultaneously inhibiting glutamate (NMDA) receptor signaling. Chronic heavy use leads to neuroadaptive changes that produce tolerance and physical dependence.

• Nicotine (tobacco and e-cigarette products): Binds to nicotinic acetylcholine receptors in the mesolimbic dopamine pathway, triggering dopamine release in the nucleus accumbens. This reward pathway activation underlies nicotine's high addictive potential — approximately 60–70% of adult smokers report wanting to quit, yet only about 7.5% who attempt cessation without pharmacotherapy succeed for 6 months or more (NIDA, 2022).

• Opioids (heroin, fentanyl, prescription analgesics): Bind to mu-opioid receptors in the brain and spinal cord, producing analgesia, euphoria, and respiratory depression. Illicitly manufactured fentanyl, which is 50–100 times more potent than morphine, drove the majority of the 107,941 overdose deaths recorded in 2022.

• Stimulants (cocaine, methamphetamine, prescription amphetamines): Increase synaptic concentrations of dopamine, norepinephrine, and serotonin through reuptake inhibition or direct release from vesicular stores. Methamphetamine-related overdose deaths doubled between 2015 and 2019 (NIDA Methamphetamine DrugFacts).

• Cannabis (delta-9-tetrahydrocannabinol / THC): Acts on cannabinoid CB1 and CB2 receptors, modulating dopamine, GABA, and glutamate signaling. Potency measured by THC concentration has risen from roughly 4% in 1995 to over 15% in commercially available flower products by 2021 (NIDA, Marijuana Potency).

The treatment infrastructure for SUDs comprises a tiered system: medically managed intensive inpatient (ASAM Level 4), residential/inpatient (Level 3), intensive outpatient (Level 2), and outpatient (Level 1), as defined by the American Society of Addiction Medicine (ASAM) Criteria. Medication-assisted treatment (MAT) — now increasingly referred to as medications for opioid use disorder (MOUD) — includes methadone (available through federally certified opioid treatment programs), buprenorphine (prescribable in general medical settings following the elimination of the X-waiver requirement in December 2022), and naltrexone.

Causal relationships or drivers

Substance use patterns emerge from a convergence of biological, environmental, and social factors rather than a single causal mechanism. The National Institute on Drug Abuse identifies the following primary driver categories:

Genetic predisposition. Twin and adoption studies estimate that genetic factors account for 40–60% of the vulnerability to developing a substance use disorder (NIDA, Genetics and Epigenetics of Addiction). Specific gene variants affecting alcohol metabolism (ADH1B, ALDH2) directly influence patterns of alcohol use, with protective ALDH2*2 alleles concentrated in East Asian populations reducing rates of alcohol use disorder.

Adverse childhood experiences (ACEs). The landmark CDC-Kaiser Permanente ACE Study demonstrated a graded dose-response relationship between cumulative childhood adversity and adult substance use. Adults reporting 5 or more ACEs had a 7- to 10-fold increased risk of illicit drug use and addiction compared to those reporting zero ACEs. This intersects directly with the social determinants of health framework, where housing instability, poverty, and exposure to violence function as upstream drivers.

Mental health comorbidity. The 2022 National Survey on Drug Use and Health (NSDUH) reported that among the 48.7 million adults with a mental illness, 24.0% also met criteria for a substance use disorder — nearly double the rate observed in adults without mental illness (SAMHSA 2022 NSDUH). The relationship between mental health conditions and substance use is extensively documented within the behavioral health explained reference and the mental health fundamentals framework.

Environmental availability and policy. Outlet density for alcohol retail, pricing through excise taxation, minimum legal purchase ages, and prescribing practices for opioid analgesics all modulate population-level substance use. States that expanded Medicaid under the Affordable Care Act saw increased access to SUD treatment and, in at least 3 published difference-in-differences analyses, reductions in opioid overdose death rates relative to non-expansion states.

Classification boundaries

The boundaries of what constitutes a "substance" and what constitutes a "disorder" are set by overlapping regulatory and clinical frameworks:

Cannabis occupies a contested classification boundary. It remains a Schedule I substance under federal law (no accepted medical use, high abuse potential per DEA classification), yet 38 states plus Washington, D.C. have enacted medical cannabis programs, and 24 states plus D.C. have legalized adult recreational use as of 2024. This federal-state tension creates complications for treatment providers, employers, and health risk factor assessment.

The distinction between substance use as a health behavior and substance use disorder as a clinical condition parallels the broader demarcation between acute vs. chronic conditions. A single episode of binge drinking is a health behavior with acute risk; repeated patterns meeting DSM-5-TR criteria constitute a chronic relapsing condition.

Tradeoffs and tensions

Harm reduction versus abstinence-only frameworks. The U.S. treatment system historically centered abstinence as the sole acceptable outcome. SAMHSA's current strategic plan explicitly endorses harm reduction approaches — including naloxone distribution, syringe services programs, and supervised consumption — as evidence-based. This creates tension with state-level policies in jurisdictions where syringe services or supervised consumption sites remain prohibited. The 2023 federal fiscal year allocated $77 million specifically for harm reduction activities through SAMHSA grants (SAMHSA Harm Reduction Grant Program).

Criminalization versus medicalization. Substance use disorders are recognized as chronic brain conditions by NIDA, the American Medical Association, and the World Health Organization, yet criminal penalties for possession and use persist across federal law and in the majority of states. Oregon's Measure 110, which decriminalized personal possession of all drugs in 2020, was substantially rolled back by HB 4002 in 2024 after increases in public drug use prompted political reversal — illustrating the instability of the policy landscape.

Prescription opioid access versus diversion risk. Tighter prescribing regulations following the CDC's 2016 Guideline for Prescribing Opioids for Chronic Pain reduced opioid prescribing rates by roughly 44% between 2012 and 2020 (CDC, U.S. Opioid Dispensing Rate Maps). Simultaneously, chronic pain patients reported reduced access to medically appropriate pain management, and the overdose crisis shifted to illicitly manufactured fentanyl. The updated 2022 CDC Clinical Practice Guideline explicitly emphasized individualized assessment over rigid dose thresholds.

Tobacco and nicotine product regulation. E-cigarettes and vaping devices present a tradeoff between their potential as less harmful alternatives for adult smokers and their documented appeal to youth. The 2024 National Youth Tobacco Survey found that 1.63 million middle and high school students reported current e-cigarette use (FDA, Youth Tobacco Use Survey Results).

Common misconceptions

"Addiction is a choice, not a disease." The neurobiological evidence base, including decades of PET imaging, genome-wide association studies, and animal models, supports classification of severe SUD as a chronic, relapsing brain disorder. The AMA recognized addiction as a disease in 1956 and has reaffirmed that position consistently. This does not eliminate the role of volitional behavior but places SUD within the same chronic disease framework as other chronic conditions.

"Switching from cigarettes to e-cigarettes is risk-free." Public Health England (now the Office for Health Improvement and Disparities) published a 2015 estimate that e-cigarettes are approximately 95% less harmful than combustible cigarettes. That figure is frequently cited out of context. The FDA has not authorized any e-cigarette as a cessation device, and emerging data on EVALI (e-cigarette or vaping product use-associated lung injury) — which hospitalized 2,807 people and caused 68 deaths in 2019–2020 (CDC EVALI Update) — demonstrates that the risk profile is non-zero.

"Moderate alcohol consumption is cardioprotective." Large-scale Mendelian randomization studies published in JAMA Network Open (2022) and the Global Burden of Disease alcohol analyses have challenged the "J-curve" hypothesis, finding that any level of alcohol consumption increases all-cause mortality risk when confounding variables are adequately controlled. The World Health Organization stated in a 2023 policy brief that "no level of alcohol consumption is safe for health."

"Marijuana is not addictive." Approximately 9% of cannabis users develop cannabis use disorder; among those who initiate use before age 18, the rate rises to approximately 17% (NIDA). The substance use and health reference page provides additional context on population-level prevalence data.

Checklist or steps (non-advisory)

The following sequence reflects the standard clinical and administrative pathway through which substance use is identified, assessed, and addressed within the U.S. healthcare and behavioral health system:

1. Screening administration. Validated instruments include the AUDIT (Alcohol Use Disorders Identification Test, 10 items), DAST-10 (Drug Abuse Screening Test), and single-item screening questions recommended by NIDA for primary care settings.
2. Brief intervention delivery. For individuals scoring in at-risk but non-dependent ranges, brief motivational interviewing (typically 5–15 minutes) occurs within the primary care encounter.
3. Comprehensive assessment. For individuals meeting screening thresholds, a licensed clinician (e.g., LCSW, LPC, or physician with addiction credentials) conducts a biopsychosocial assessment using ASAM Criteria dimensions.
4. Level-of-care determination. Based on the six ASAM dimensions — intoxication/withdrawal potential, biomedical conditions, emotional/behavioral conditions, readiness to change, relapse/continued use potential, and recovery environment — a treatment level (1 through 4) is assigned.
5. Treatment plan development. A written individualized treatment plan specifying measurable goals, expected duration, and interventions is created in compliance with 42 CFR Part 2 confidentiality requirements.
6. Pharmacotherapy initiation (if indicated). For opioid use disorder: methadone, buprenorphine, or naltrexone. For alcohol use disorder: naltrexone, acamprosate, or disulfiram. For tobacco: varenicline, bupropion, or nicotine replacement therapy.
7. Ongoing monitoring and recovery support. Includes physical health indicators tracking, drug testing when clinically appropriate, peer support services, and transition planning.

The home page of this reference authority provides navigation to related domains that intersect with substance use, including stress and health, nutrition and health, and health equity and disparities.

Reference table or matrix

| Substance Category | Primary Mechanism | DEA Schedule | Estimated Annual U.S. Deaths | FDA-Approved Pharmacotherapy for Use Disorder |
|---|---|---|---|